• European Patent Office issued intention to grant midkine...

• European Patent Office issued intention to grant midkine antibody patent which covers one of the lead drugs in Cellmid’s midkine program
• This patent provides comprehensive protection over midkine antibodies in several disease settings including cancer, inflammatory diseases and autoimmune conditions
• Important milestone in clinical development program for midkine assets
• Significant value-add to the midkine patent portfolio for partnering

It adds value because Pfizer is running an array of Glioblastoma trials and they co-funded the Complutense pre-clinical study AND because the midkine antibody works in conjunction with other chemo.

My suggestion is the Pfizer will take this forward because of the results thus far.